Interní Med. 2010; 12(9): 427-430

Clinical use of the new antithrombotics

doc.MUDr.Petr Dulíček, Ph.D.
II. interní klinika –, Oddělení klinické hematologie, FN a LF v Hradci Králové

Venous thromboembolism is a major medical and social economical problem. However, it is a big challenge because it is possible to

eliminate this disease by appropriate thromboprophylaxis. Unfractionated heparin hase been the therapy of choice for many years, but

it was replaced by low molecular heparin in the last 20 years. New antithrombotic have come up in clinical praxis recently. There are 2

new drugs with a different mechanism of action. Dabigatran etexilate is direct trombin inhibitor, rivaroxaban is direct FXa inhibitor. In

our article, we discuss current knowledge of these drugs and the possibility of use in the clinical praxis.

Keywords: venous thromboembolism, prophylaxis, dabigatran, rivaroxaban

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P. Clinical use of the new antithrombotics. Interní Med. 2010;12(9):427-430.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nordström M, Lindblad B, Bergvist D, et al. A prospective study of the incidence of deep vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155-160. Go to original source... Go to PubMed...
    2. Turpie AGG. New approaches to anticoagulation: Oral factor Xa inhibitors. Thromb Haemost: New perspectives, new strategies in venous thromboembolic disease. A satellite symposium at the 50th ASH Annual Meeting: 2008; (Suppl.): 16-20.
    3. Virchow R. Trombose und Embolie. Vol Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Berlin: Verlag Maxirsch: 1865; 219.
    4. Geerts WH, Bergqvist D, Pineo G, et al. Prevention of venous thromboembolism: American College of Chest Physicians, Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381-453. Go to original source...
    5. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non inferiority trial. Lancet 2007; 370: 949-956. Go to original source... Go to PubMed...
    6. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL study Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185. Go to original source... Go to PubMed...
    7. The RE-MOBILIZE writing Committee. The oral thrombin inhibitor dabigatran etexilate vs. the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9. Go to original source... Go to PubMed...
    8. Conolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    9. Schulman S, Kearon C, Kakkar AK. Dabigatran versus Warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352. Go to original source... Go to PubMed...
    10. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775. Go to original source... Go to PubMed...
    11. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double - blind, randomized controlled trial. Lancet 2008; 372: 31-39. Go to original source... Go to PubMed...
    12. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus Enoxaparin for the thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. Go to original source... Go to PubMed...
    13. Turpie AGG, Larsen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for the thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009; 373: 1673-1680. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.